Actively Recruiting
Evaluating Safety and Preliminary Activity of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Led by Allist Pharmaceuticals, Inc. · Updated on 2026-08-13
104
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, drug levels, and preliminary antitumor activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer NSCLC that have a KRAS p.G12C mutation combined with an STK11 co-mutation and wild-type KEAP1. This open-label study includes participants who are either treatment-nave or have had at least one prior therapy for advanced disease. The study consists of a dose escalation phase where JAB-21822 is given orally as a monotherapy to determine the maximum tolerated dose and recommended phase 2 dose. This is followed by two dose expansion parts one with participants previously untreated and another with participants who received at least one prior systemic therapy. The treatment is administered continuously in 21-day cycles, with safety and clinical activity monitored throughout. Participants will be closely monitored with assessments including adverse event tracking, pharmacokinetics drug levels in plasma, and tumor response evaluations according to RECIST criteria. The primary outcomes include dose limiting toxicities in the first cycle, objective response rate during the dose expansion, and longer-term safety over up to three years. The total study duration extends up to three years, allowing detailed evaluation of treatment effects and safety over time.
CONDITIONS
Brief Title
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Research Team
S
Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd
W
Wang Jie Wang Jie M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here